MA43347B1 - Compositions et méthodes permettant d'inhiber l'expression du gène de lpa - Google Patents

Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Info

Publication number
MA43347B1
MA43347B1 MA43347A MA43347A MA43347B1 MA 43347 B1 MA43347 B1 MA 43347B1 MA 43347 A MA43347 A MA 43347A MA 43347 A MA43347 A MA 43347A MA 43347 B1 MA43347 B1 MA 43347B1
Authority
MA
Morocco
Prior art keywords
agents
gene expression
compositions
methods
lpa
Prior art date
Application number
MA43347A
Other languages
English (en)
Other versions
MA43347A (fr
Inventor
Steven Kanner
David Rozema
David Lewis
Lauren Almeida
Darren Wakefield
Vladimir Trubetskoy
Tao Pei
Zhen Li
Aaron Almeida
Original Assignee
Arrowhead Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc
Publication of MA43347A publication Critical patent/MA43347A/fr
Publication of MA43347B1 publication Critical patent/MA43347B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3517—Marker; Tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Des agents d'interférence d'arn (arni) et des conjugués d'agents d'arni pour inhiber l'expression du gène de la lpa (apo (a)) sont décrits. Des compositions pharmaceutiques comprenant un ou plusieurs agents arni lpa, éventuellement avec un ou plusieurs agents thérapeutiques supplémentaires, sont également décrites. La délivrance des agents arni lpa décrits aux cellules hépatiques in vivo permet d'inhiber l'expression du gène lpa et le traitement des maladies cardiovasculaires et cardiovasculaires.
MA43347A 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa MA43347B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562235816P 2015-10-01 2015-10-01
US201662346304P 2016-06-06 2016-06-06
US201662383221P 2016-09-02 2016-09-02
PCT/US2016/054729 WO2017059223A2 (fr) 2015-10-01 2016-09-30 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Publications (2)

Publication Number Publication Date
MA43347A MA43347A (fr) 2018-08-08
MA43347B1 true MA43347B1 (fr) 2021-11-30

Family

ID=58424351

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43347A MA43347B1 (fr) 2015-10-01 2017-04-06 Compositions et méthodes permettant d'inhiber l'expression du gène de lpa

Country Status (35)

Country Link
US (4) US9932586B2 (fr)
EP (2) EP3356529B1 (fr)
JP (5) JP6991966B2 (fr)
KR (3) KR102942707B1 (fr)
AU (3) AU2016331084B2 (fr)
CA (2) CA3000397A1 (fr)
CL (1) CL2018000803A1 (fr)
CO (1) CO2018003678A2 (fr)
CR (1) CR20180231A (fr)
CY (1) CY1125263T1 (fr)
DK (1) DK3356529T3 (fr)
EA (1) EA038478B1 (fr)
ES (1) ES2896298T3 (fr)
HR (1) HRP20211410T1 (fr)
HU (1) HUE055942T2 (fr)
IL (3) IL258333B (fr)
JO (2) JOP20160211B1 (fr)
LT (1) LT3356529T (fr)
MA (1) MA43347B1 (fr)
MX (2) MX2018003833A (fr)
MY (1) MY195796A (fr)
PE (1) PE20181139A1 (fr)
PH (1) PH12018500713A1 (fr)
PL (1) PL3356529T3 (fr)
PT (1) PT3356529T (fr)
RS (1) RS62523B1 (fr)
SG (1) SG10202008530TA (fr)
SI (1) SI3356529T1 (fr)
SM (1) SMT202100622T1 (fr)
TN (1) TN2018000094A1 (fr)
TW (4) TWI784934B (fr)
UA (1) UA121998C2 (fr)
UY (1) UY36926A (fr)
WO (1) WO2017059223A2 (fr)
ZA (1) ZA202106265B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7718133B2 (en) 2003-10-09 2010-05-18 3M Innovative Properties Company Multilayer processing devices and methods
JOP20170057B1 (ar) * 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية
JOP20170056B1 (ar) 2016-09-02 2021-08-17 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة
US11015198B2 (en) * 2017-04-05 2021-05-25 Silence Therapeutics Gmbh Products and compositions
TN2019000308A1 (en) * 2017-07-06 2021-05-07 Arrowhead Pharmaceuticals Inc RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE
SG11201912178VA (en) * 2017-09-11 2020-01-30 Arrowhead Pharmaceuticals Inc Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
MX2020001912A (es) * 2017-09-14 2020-03-24 Arrowhead Pharmaceuticals Inc Agentes de iarn y composiciones para inhibir la expresion de la angiopoyetina tipo 3 (angptl3) y metodos de uso.
SG11202003126VA (en) 2017-10-04 2020-05-28 Avidity Biosciences Inc Nucleic acid-polypeptide compositions and uses thereof
CN111212909A (zh) * 2017-10-17 2020-05-29 箭头药业股份有限公司 用于抑制去唾液酸糖蛋白受体1的表达的RNAi试剂和组合物
CN119120476A (zh) * 2017-11-13 2024-12-13 赛伦斯治疗有限责任公司 用于抑制细胞中lpa的表达的核酸
EP3483270A1 (fr) * 2017-11-13 2019-05-15 Silence Therapeutics GmbH Produits et compositions
US12534728B2 (en) * 2018-09-19 2026-01-27 Arrowhead Pharmaceuticals, Inc. RNAi agents for inhibiting expression of 17beta-HSD type 13 (HSD17B13), compositions thereof, and methods of use
AU2019380628B2 (en) * 2018-11-13 2024-10-31 Silence Therapeutics Gmbh Nucleic acids for inhibiting expression of LPA in a cell
WO2020247782A1 (fr) 2019-06-06 2020-12-10 Avidity Biosciences, Inc. Compositions d'acide nucléique-polypeptide et utilisations de celles-ci
EP3983077A4 (fr) * 2019-06-17 2023-12-20 Alnylam Pharmaceuticals, Inc. Administration d'oligonucléotides au striatum
CN112442499B (zh) * 2019-08-30 2026-03-10 恩康药业科技（广州）有限公司 一种抑制MCM7的siRNA、组合物及其应用
JP7827623B2 (ja) * 2019-12-09 2026-03-10 アムジエン・インコーポレーテツド ＬＰＡ発現を阻害するためのＲＮＡｉコンストラクト及び方法
EP4126967A1 (fr) * 2020-03-23 2023-02-08 Amgen Inc. Anticorps monoclonaux pour acides nucléiques modifiés chimiquement et leurs utilisations
KR20220158011A (ko) * 2020-03-26 2022-11-29 애로우헤드 파마슈티컬스 인코포레이티드 PNPLA3의 발현을 억제하기 위한 RNAi 작용제, 이의 약제학적 조성물, 및 사용 방법
KR20250077604A (ko) * 2020-08-05 2025-05-30 다이서나 파마수이티컬, 인크. Lpa 발현을 저해하기 위한 조성물 및 방법
EP4229201A1 (fr) * 2020-10-16 2023-08-23 Sanofi Compositions d'arn et méthodes d'inhibition de lipoprotéine (a)
KR20230104200A (ko) * 2020-11-05 2023-07-07 암젠 인크 LPA-표적화된 RNAi 작제물을 이용하여 죽상경화성 심혈관질환을 치료하는 방법
WO2022121959A1 (fr) * 2020-12-09 2022-06-16 纳肽得有限公司 Molécule d'arnsi et son application dans le traitement de maladies des artères coronaires
US20250304966A1 (en) 2020-12-23 2025-10-02 Argonaute RNA Limited Treatment of cardiovascular disease
US20250034561A1 (en) * 2021-02-18 2025-01-30 Oneglobe Holdings Limited Novel Compositions for Conjugating Oligonucleotides and Carbohydrates
CN117836307A (zh) 2021-06-18 2024-04-05 弘景生物科技有限公司 功能化的n-乙酰基半乳糖胺核苷
EP4396193A4 (fr) 2021-08-30 2025-07-02 Hongene Biotech Corp Analogues de n-acétylgalactosamine fonctionnalisés
US20250283076A1 (en) 2021-09-14 2025-09-11 Argonaute RNA Limited Treatment of cardiovascular disease
KR20240103025A9 (ko) 2021-11-16 2025-12-10 상하이 아르고 바이오파마슈티칼 씨오., 엘티디. 안지오텐시노겐(agt) 단백질의 발현을 저해하는 조성물 및 방법
CN118401539A (zh) 2021-12-15 2024-07-26 兆维生物科技公司 官能化的n-乙酰半乳糖胺类似物
EP4450624A4 (fr) * 2021-12-16 2025-03-26 Tuojie Biotech (Shanghai) Co., Ltd. Arnsi ciblant le lpa et conjugué
CN115851723B (zh) * 2022-10-24 2023-10-03 厦门甘宝利生物医药有限公司 一种抑制lpa基因表达的rna抑制剂及其应用
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
KR20250131826A (ko) * 2023-01-13 2025-09-03 일라이 릴리 앤드 캄파니 치료 올리고뉴클레오티드-함유 제약 조성물 및 그를 사용한 투여 요법
AU2024279456A1 (en) * 2023-05-31 2025-12-04 Arrowhead Pharmaceuticals, Inc. HEPATIC DELIVERY PLATFORMS FOR MULTIMERIC RNAi AGENT CONJUGATES AND METHODS OF USE THEREOF
KR20260020955A (ko) 2023-05-31 2026-02-12 투오지에 바이오텍 (상하이) 컴퍼니 리미티드 LPA를 표적화하는 dsRNA 및 이의 응용
DE102023115075A1 (de) * 2023-06-07 2024-12-12 B.Braun Avitum Ag Schlauchrollenpumpe
UY40897A (es) 2023-09-21 2025-03-31 Ionis Pharmaceuticals Inc Compuestos y métodos para inhibir lpa
TW202540420A (zh) 2023-11-15 2025-10-16 大陸商北京加科瑞康醫藥科技有限公司 用於抑制LPA的基因表現的siRNA，含其的組合物及其用途
WO2026092650A1 (fr) * 2024-11-01 2026-05-07 迈威(上海)生物科技股份有限公司 Préparation d'arni destinée à inhiber l'expression du gène lpa et utilisation associée
WO2026133253A1 (fr) 2024-12-20 2026-06-25 Novartis Ag Combinaisons d'agents antisens, compositions pharmaceutiques et procédés d'utilisation
CN120485189B (zh) * 2025-07-16 2025-10-17 北京悦康科创医药科技股份有限公司 靶向调控LPA基因表达的siRNA及其用途

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9201440A (nl) 1992-08-11 1994-03-01 Univ Leiden Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en) 1994-09-23 1997-02-04 Stinchcomb; Dan T. Ribozymes targeted to apo(a) mRNA
WO2000053722A2 (fr) 1999-03-10 2000-09-14 Phogen Limited Administration de substances a des cellules
CN100523215C (zh) * 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
DE602004027798D1 (de) 2003-03-12 2010-08-05 Univ Arizona State Verfahren zur regulierung von angiogenese mit apelin-zusammensetzungen
CA2559955C (fr) 2004-03-15 2016-02-16 City Of Hope Procedes et compositions pour l'inhibition specifique de l'expression genetique par l'arn double brin
US8658211B2 (en) * 2006-08-18 2014-02-25 Arrowhead Madison Inc. Polyconjugates for in vivo delivery of polynucleotides
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (fr) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Molécules d'arn interférence substrats de dicer multiplexes ayant des séquences de jonction
PH12012501596A1 (en) 2010-02-24 2017-02-03 Arrowhead Res Corporation Compositions for targeted delivery of sirna
WO2011141703A1 (fr) * 2010-05-12 2011-11-17 Protiva Biotherapeutics Inc. Compositions et procédés pour réduire au silence l'apolipoprotéine b
US8501930B2 (en) 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
RU2013117288A (ru) * 2010-12-17 2015-01-27 Эрроухэд Рисерч Корпорейшн СОДЕРЖАЩАЯ ГАЛАКТОЗНЫЙ КЛАСТЕР НАЦЕЛИВАЮЩАЯ ГРУППА ДЛЯ миРНК, МОДУЛИРУЮЩАЯ ФОРМАКОКИНЕТИЧЕСКИЕ СВОЙСТВА
MX347298B (es) 2010-12-29 2017-04-21 Arrowhead Res Corp Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima.
CA2842039A1 (fr) 2011-08-26 2013-03-07 Arrowhead Research Corporation Polymeres poly(ester vinyliques) pour administration d'acide nucleique in vivo
MX2014001965A (es) 2012-04-18 2014-03-31 Arrowhead Res Corp Polimeros de poli(acrilato) para suministro de acido nucleico in vivo.
RU2624028C2 (ru) * 2012-05-24 2017-06-30 Ионис Фармасьютикалз, Инк. Способы и композиции для модулирования экспрессии аполипопротеина (а)
HK1219422A1 (zh) * 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
PL2992098T3 (pl) 2013-05-01 2019-09-30 Ionis Pharmaceuticals, Inc. Kompozycje i sposoby modulowania ekspresji hbv i ttr
WO2015021092A1 (fr) * 2013-08-07 2015-02-12 Arrowhead Research Corporation Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo
US20160272970A1 (en) 2015-03-17 2016-09-22 Arrowhead Madison Inc. RNA Interference Agents
TWI761305B (zh) 2015-05-29 2022-04-21 美商愛羅海德製藥公司 抑制Ｈｉｆ２α基因表現之組合物及方法
LT3329002T (lt) * 2015-07-31 2021-01-11 Alnylam Pharmaceuticals, Inc. Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
JOP20170057B1 (ar) 2016-03-07 2022-03-14 Arrowhead Pharmaceuticals Inc مركبات ترابطية مستهدفة كمركبات علاجية

Also Published As

Publication number Publication date
AU2022283623B2 (en) 2025-07-10
JP2024009262A (ja) 2024-01-19
EP3356529A2 (fr) 2018-08-08
DK3356529T3 (da) 2021-11-08
UY36926A (es) 2017-04-28
KR102728481B1 (ko) 2024-11-12
US9932586B2 (en) 2018-04-03
WO2017059223A9 (fr) 2017-08-17
AU2016331084A1 (en) 2018-04-19
KR20260046241A (ko) 2026-04-06
CO2018003678A2 (es) 2018-11-30
NZ741086A (en) 2023-11-24
PL3356529T3 (pl) 2021-12-20
PT3356529T (pt) 2021-11-04
EP4029941A1 (fr) 2022-07-20
TWI880645B (zh) 2025-04-11
IL290566A (en) 2022-04-01
PE20181139A1 (es) 2018-07-17
JOP20160211B1 (ar) 2021-08-17
SI3356529T1 (sl) 2022-01-31
JP7116212B2 (ja) 2022-08-09
AU2025242219A1 (en) 2025-10-23
US20200263179A1 (en) 2020-08-20
TWI784934B (zh) 2022-12-01
EA038478B1 (ru) 2021-09-03
MX2022013010A (es) 2022-11-09
KR20240162596A (ko) 2024-11-15
TW202449154A (zh) 2024-12-16
AU2016331084B2 (en) 2022-09-08
JP7442574B2 (ja) 2024-03-04
EP3356529A4 (fr) 2019-09-04
CL2018000803A1 (es) 2018-08-31
BR112018006489A2 (pt) 2018-10-09
WO2017059223A2 (fr) 2017-04-06
JP2021087459A (ja) 2021-06-10
HRP20211410T1 (hr) 2021-12-24
IL258333A (en) 2018-05-31
IL300438B2 (en) 2026-07-01
MY195796A (en) 2023-02-21
TW202332769A (zh) 2023-08-16
WO2017059223A3 (fr) 2017-05-11
CR20180231A (es) 2018-05-31
MX2018003833A (es) 2018-06-18
US20180195070A1 (en) 2018-07-12
KR102942707B1 (ko) 2026-03-23
SMT202100622T1 (it) 2022-01-10
HUE055942T2 (hu) 2022-01-28
HK1259063A1 (en) 2019-11-22
KR20180052703A (ko) 2018-05-18
CA3310628A1 (en) 2026-06-21
EA201890864A1 (ru) 2018-09-28
IL300438B1 (en) 2026-03-01
MA43347A (fr) 2018-08-08
JP2022113835A (ja) 2022-08-04
JP6991966B2 (ja) 2022-02-03
NZ780687A (en) 2025-06-27
US20250115907A1 (en) 2025-04-10
JP2018529732A (ja) 2018-10-11
CN108368506A (zh) 2018-08-03
TWI836693B (zh) 2024-03-21
ZA202106265B (en) 2023-08-30
TW202600825A (zh) 2026-01-01
EP3356529B1 (fr) 2021-08-25
AU2022283623A1 (en) 2023-02-02
IL290566B1 (en) 2023-03-01
IL290566B2 (en) 2023-07-01
SG10202008530TA (en) 2020-10-29
UA121998C2 (uk) 2020-08-25
JOP20210043A1 (ar) 2021-03-08
PH12018500713A1 (en) 2018-10-15
CA3000397A1 (fr) 2017-04-06
US10662427B2 (en) 2020-05-26
ES2896298T3 (es) 2022-02-24
IL258333B (en) 2022-03-01
TW201726918A (zh) 2017-08-01
IL300438A (en) 2023-04-01
US20170096665A1 (en) 2017-04-06
JP2026040461A (ja) 2026-03-09
RS62523B1 (sr) 2021-11-30
TN2018000094A1 (en) 2019-07-08
LT3356529T (lt) 2021-12-27
CY1125263T1 (el) 2023-03-24

Similar Documents

Publication Publication Date Title
MA43347A (fr) Compositions et méthodes permettant d'inhiber l'expression du gène de lpa
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
PH12020500309A1 (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
WO2018140920A8 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
HK1203356A1 (en) Pharmaceutical combinations comprising a thionucleotide analog
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2021013582A (es) Composiciones que comprenden agentes biologicamente activos y sales biliares.
PH12012501755A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
EA201692318A1 (ru) Композиции и способы для ингибирования экспрессии гена альфа-1-антитрипсина
MA40791A (fr) Ciblage lysosomal d'enzymes et utilisations associées
JOP20190263A1 (ar) عوامل RNAi لتثبيط التعبير عن Alpha- EnaC وطرق استخدامها
HK1252852A1 (zh) 阻止HIF2α基因表达的组合物及方法
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
WO2016100738A3 (fr) Activité antifibrotique d'inhibiteur de gas6
WO2016030899A8 (fr) Méthodes de traitement de la sclérose latérale amyotrophique
PH12017502081A1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
GB201302343D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods for using the same
AU2017260019A1 (en) Valerian composition and related methods
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
CR20200117A (es) Agentes de iarn y composiciones para inhibir la expresión de la angiopoyetina tipo 3 (angptl3) y métodos de uso
EA202090234A1 (ru) СРЕДСТВА РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АЛЬФА-ENaC И СПОСОБЫ ПРИМЕНЕНИЯ
EA202090717A1 (ru) СРЕДСТВА И КОМПОЗИЦИИ РНКи ДЛЯ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ АНГИОПОЭТИН-ПОДОБНОГО БЕЛКА 3 (ANGPTL3) И СПОСОБЫ ПРИМЕНЕНИЯ